Airsculpt Technologies, Inc. AIRS
Medical/Nursing Services · IPO 2021 · data as of November 13, 2026
Airsculpt Technologies, Inc. (AIRS) is a healthcare company listed in the US with a market value of about $62M. In the twelve months to September 30, 2026 it had revenue of $148M and net income of -$9M, a net margin of -6.4%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is track record (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 19% a year, a 5-year average ROIC of 1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 10% below the current price.
About Airsculpt Technologies
Airsculpt Technologies is listed in the US and classified in medical/nursing services, IPO year 2021. Revenue went from $41M in 2019 to $152M in 2025, growth of about 24.3% a year. It was profitable in 2 of the last 7 years in our data. Its share count rose by 9% over three years (dilution for shareholders).
Score: 0.6 / 5
Checks passed
- 5-year revenue growth above 8% a year
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $148M | $152M | $180M | $196M | $169M | $133M | $63M | $41M |
| Net income | -$9M | -$12M | -$8M | -$4M | -$15M | $11M | $8M | -$2M |
| Free cash flow | -$3M | $692000 | -$3M | $14M | $12M | $20M | $10M | $499000 |
| EPS (diluted) | $-0.12 | $-0.19 | $-0.14 | $-0.08 | $-0.26 | $-0.01 | — | — |
| Net margin | -6.4% | -7.7% | -4.5% | -2.2% | -8.7% | 7.9% | 12.1% | -5.4% |
| ROIC | — | -4.5% | -0.7% | 4.2% | -2.0% | 8.3% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Airsculpt Technologies stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 10% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Airsculpt Technologies pay a dividend?
Not currently.
Is Airsculpt Technologies a good stock to buy?
We do not give buy or sell advice. Airsculpt Technologies scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.